市场调查报告书
商品编码
1408722
喉镜刀片市场:现况分析与预测(2023-2030)Laryngoscope Blades Market: Current Analysis and Forecast (2023-2030) |
由于寻找潜在诊断系统的产品批准不断增加,因此喉镜刀片市场预计在预测期内将以 5.1% 的复合年增长率强劲增长。 例如,2022 年 7 月,高性能一次性内视镜领先开发商 Zsquare 的首款产品 Zsquare ENT-Flex 鼻喉镜获得 FDA 的营销许可。 其他几个因素也导致了市场激增,包括产品发布数量的增加、研究投资、患者治疗效果的改善以及企业合作关係。 例如,PROACT Medical 于 2022 年 11 月在欧洲市场推出了一系列创新一次性喉镜。
依类型划分,市场分为直刀片和弯刀片。 弯曲刀片段由于其窄凸缘可以控制舌头并减少对牙龈和牙齿的创伤,因此在 2022 年占据了最高的市场份额。 这种类型的刀片更适合年龄较大的孩子。 对微创诊断的需求不断增长以及创新产品的推出导致了该领域的显着增长。 因此,到2022年,弯曲叶片部分将在市场上占据主要份额。
根据可用性,市场分为一次性和可重复使用。 预计可重复使用部分在预测期内将以最高复合年增长率成长。 这种增长归因于可重复使用刀片的成本效率和长生命週期。 由于吸烟和酗酒等不良生活方式的改变,导致喉癌和肺癌的发病率增加,以及人们对肺癌和喉癌等慢性病的认识不断提高,该细分市场获得了市场主导地位。我是。 例如,美国癌症协会预测,2022年美国将新增约12,470例喉癌病例,其中男性9,820例,女性2,650例。 因此,可重复使用部分预计将在预测期内主导市场。
根据最终用户,市场分为医院、门诊手术中心等。 医院类别是根据医院提供医疗保健的便利性、高素质医疗人员的可用性、先进医疗技术的利用以及世界各地单位数量的多样化而按医院分类的。2022 年 市场。 例如,根据美国医院协会2023年的数据,2022年美国共有6,129家医院,拥有919,649张临床床位和34,011,386名住院病患。 医院领域的市场竞争非常激烈,预计这种情况在可预见的未来仍将持续。 因此,2022年的市场规模将由医院产业主导。
为了更了解喉镜刀片产业的市场实施情况,将市场分为北美(美国、加拿大、北美其他地区)、欧洲(德国、英国、法国、西班牙、义大利、欧洲其他地区) 、亚太地区(根据世界其他地区(中国、日本、印度、亚太其他地区)和世界其他地区的全球影响力进行分析。 预计亚太地区在预测期内将以最高复合年增长率成长。 这是由于市场上存在着大公司、癌症发病率不断上升以及完善的学术研究机构的存在。 印度和中国等国家为临床研究提供了有吸引力的投资机会,预计将积极推动喉镜刀片的研发。 因此,由于亚太地区人口规模庞大,预计在预测期内将以更高的复合年增长率成长。
A laryngoscope blade is a medical device used in conjunction with a laryngoscope handle during intubation procedures. It helps visualize the larynx by lifting the tongue and epiglottis, allowing a clear passage for intubation. Blades come in various shapes and sizes to accommodate different patient anatomies and clinical needs. The laryngoscope blade market is growing at a tremendous rate owing to a surge in the number of chronic diseases such as lung and throat cancer. For instance, in 2020, the International Agency for Research on Cancer and the World Health Organization conducted a GLOBOCAN study on global cancer incidence and prevalence. According to the results of the study, there were approximately 308,102 new cases diagnosed in the U.S. Other factors such as increased focus on early detection and prevention, advances in diagnostics, rising product launch and product approval for laryngoscope systems, and a rise in the senior population are driving factors for the market.
The Laryngoscope Blades Market is expected to grow at a strong CAGR of 5.1% during the forecast period owing to the rising product approvals for finding a potential diagnostic system. For instance, in July 2022, a leading developer of high-performance, single-use endoscopes Zsquare, got FDA clearance to market its first product, the Zsquare ENT-Flex Rhinolaryngoscope. Several other factors such as an increased number of product launches, investment in research, improved patient outcomes, and company collaborations are also leading to the surge in the market. For instance, PROACT Medical launched an innovative new line of single-use laryngoscopes in the European market in November 2022.
Based on types, the market is bifurcated into straight blade and curved blade. The curved blade segment held the highest share in the market in the year 2022 owing to its narrower flange which can control the tongue and decrease trauma to the gingiva and teeth. This type of blade is more suitable for older children. The increased need for minimally invasive diagnostics and innovative product launches have led to significant growth in this segment. Hence, the curved blade segment held a significant share of the market in the year 2022.
Based on usability, the market is bifurcated into disposable, and reusable. The reusable segment is expected to grow with the highest CAGR during the forecast period. This growth is attributed to the cost efficiency and longer life cycle of the reusable blades. This segment is gaining market dominance due to an adaptation of a bad lifestyle comprising of smoking and alcohol that has increased the incidences of throat and lung cancers, and increased awareness of chronic conditions such as lung and throat cancer. For instance, the American Cancer Society estimates that in 2022, there will be about 12,470 new cases of laryngeal cancer including 9,820 men and 2,650 women in the U.S. Thus, the reusable segment is expected to gain prominence in the market in the forecast period.
Based on end-users, the market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals category held the highest share in the market in 2022 attributed to the ease of access to healthcare provided by hospitals, the availability of highly qualified healthcare personnel, the utilization of advanced medical technology, and a diverse number of units all over the globe. For instance, according to the American Hospital Association in 2023, there are in total of 6,129 hospitals in the U.S with 919,649 staffed beds and 34,011,386 hospital admissions in the year 2022. The market for the hospital segment is highly competitive and is projected to remain so in the foreseeable future. Thus, the hospital segment held dominance in the market in the year 2022.
For a better understanding of the market adoption of the laryngoscope blades industry, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is expected to grow with the highest CAGR during the forecast period. This is due to the presence of major players in the market, the increasing incidence of cancers, and the presence of well-established academic and research institutes. Countries such as India and China offer attractive investment opportunities for clinical research and are anticipated to positively drive research and development prospects for laryngoscope blades. Hence, given the large population size of APAC, it is expected to grow with a high CAGR during the forecast period.
Some of the major players operating in the market include: Teleflex Incorporated; Olympus Corporation; Ambu A/S; HOYA Corporation; Stryker; Henke Sass Wolf GmbH; FUJIFILM Corporation; Hartwell Medical LLC; Medtronic; Smiths Group plc.